Eucrates Biomedical Acquisition Corp.

Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) is a blank-check company formed to pursue a merger or acquisition in the biomedical and life sciences sector. The company filed its annual report on Form 10-K with the SEC on April 13, 2023, accession number 0001410578-23-000637, documenting its activities as an active search-stage SPAC. Eucrates Biomedical completed its initial public offering in 2022 and has focused its target search on innovative healthcare and biotechnology businesses. The filing reflects the company's continued efforts to identify and evaluate prospective combination candidates within the life sciences space. Visit SpacDesk and sign up for full data, filings, and deal-tracking on EUCR and hundreds of other SPACs.